{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:39:57Z","timestamp":1779248397634,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic inflammatory skin diseases (CISDs) are among the most common diseases in the Western world. Current estimates of medical care for CISDs are primarily based on surveys among patients in medical care facilities and on health insurance data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Survey-based examination to what extent CISD patients in health-aware environment consider their skin disease to be controlled.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The survey of CISD patients was carried out in 2022 among the employees of a pharmaceutical company located in Germany and Switzerland. Software-based, anonymous, self-reported questionnaires were used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of employees, who answered the questionnaire, was 905. Of these, 222 participants (24.5%) reported having at least one CISD. 28.7% of participants with CISD described their disease as being hardly or not controlled. Regarding the nature of disease, more than one third of participants suffering from hidradenitis suppurativa (HS) or psoriasis fell into the hardly\/not controlled category. In contrast, the largest proportion of participants with chronic spontaneous urticaria (43%) or atopic dermatitis (42%) considered their CISD to be completely or well controlled. Only 35.5% of CISD sufferers stated that they were currently under medical care for their skin condition. Being under medical care, however, had no influence on the extent CISD sufferers considered their skin disease to be controlled. The number of active CISD episodes but not the total number of symptomatic days per year was negatively associated with poor disease control (<jats:italic>p<\/jats:italic>\u2009=\u20090.042 and <jats:italic>p<\/jats:italic>\u2009=\u20090.856, respectively). Poor disease control had a negative effect on the personal and professional lives of those affected, as deduced from its positive association with the extent of daily activity impairment and presenteeism (<jats:italic>p<\/jats:italic>\u2009=\u20090.005 and <jats:italic>p<\/jats:italic>\u2009=\u20090.005, respectively). Moreover, 41.4 and 20.7% of participants with hardly\/not controlled disease stated that their CISD had a moderate and severe or very severe impact on their overall lives (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), respectively. A severe or very severe impact of their CISD on their overall life was most commonly reported by participants with HS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Medical care for CISDs, even in an environment with high socio-economic standard and high health-awareness, still appears to be limited and has a negative impact on individuals and society.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1384055","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T05:08:45Z","timestamp":1713416925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Patient-reported assessment of medical care for chronic inflammatory skin diseases: an enterprise-based survey"],"prefix":"10.3389","volume":"11","author":[{"given":"Kerstin","family":"Wolk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Schielein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fontaine","family":"Widmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Wanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Fischmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/jdv.18050","article-title":"Prevalence of Most common skin diseases in Europe: a population-based study","volume":"36","author":"Richard","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat","year":"2019","journal-title":"Semin Immunopathol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/all.15486","article-title":"Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis","volume":"78","author":"Zhang","year":"2023","journal-title":"Allergy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jaci.2020.03.041","article-title":"Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type-specific immune regulation in atopic dermatitis","volume":"146","author":"Rojahn","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2004.07.007","article-title":"Il-22 increases the innate immunity of tissues","volume":"21","author":"Wolk","year":"2004","journal-title":"Immunity"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the Il-23 and Il-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.4049\/jimmunol.2200530","article-title":"Mcam+Cd161-Th17 subset expressing Cd83 enhances Tc17 response in psoriasis","volume":"210","author":"Maeda","year":"2023","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jaci.2023.03.035","article-title":"Differential regulation of Il-17a and Il-17f via Stat5 contributes to psoriatic disease","volume":"152","author":"Cole","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.immuni.2019.09.021","article-title":"Genome-wide analyses of chromatin state in human mast cells reveal molecular drivers and mediators of allergic and inflammatory diseases","volume":"51","author":"Cildir","year":"2019","journal-title":"Immunity"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.12.021","article-title":"Solar Urticaria involves rapid mast cell Stat3 activation and neutrophil recruitment, with Fcepsilonri as an upstream regulator","author":"Rutter","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis Suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of Il-22 contributes to a chronic inflammatory disease: Pathogenetic mechanisms in acne Inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bjd.19795","article-title":"Activity and components of the granulocyte Colony-stimulating factor pathway in hidradenitis Suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaci.2022.10.034","article-title":"Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis Suppurativa","volume":"151","author":"Sabat","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"875492","DOI":"10.3389\/fmed.2022.875492","article-title":"Unmet medical needs in chronic, non-communicable inflammatory skin diseases","volume":"9","author":"Ujiie","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"676241","DOI":"10.3389\/fmed.2021.676241","article-title":"Features associated with quality of life impairment in hidradenitis Suppurativa patients","volume":"8","author":"Schneider-Burrus","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of atopic dermatitis-what does the evidence say?","volume":"151","author":"Thyssen","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1080\/09546634.2022.2089329","article-title":"Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity","volume":"33","author":"Enos","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1008145","DOI":"10.3389\/falgy.2022.1008145","article-title":"Comorbidities of chronic Urticaria: a glimpse into a complex relationship","volume":"3","author":"Papapostolou","year":"2022","journal-title":"Front Allergy"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4168\/aair.2023.15.5.636","article-title":"Atopic dermatitis and the risk of myocardial infarction and all-cause mortality: a Nationwide population-based cohort study","volume":"15","author":"Woo","year":"2023","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/bjd.17578","article-title":"Substantially reduced life expectancy in patients with hidradenitis Suppurativa: a Finnish Nationwide registry study","volume":"180","author":"Tiri","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/bjd\/ljac027","article-title":"The impact of hidradenitis Suppurativa on professional life","volume":"188","author":"Schneider-Burrus","year":"2023","journal-title":"Br J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/cts.13546","article-title":"The evolving landscape of immunotherapy for the treatment of allergic conditions","volume":"16","author":"Pandya","year":"2023","journal-title":"Clin Transl Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1089\/jir.2023.0105","article-title":"Biology of Interleukin-17 and novel therapies for hidradenitis Suppurativa","volume":"43","author":"Sabat","year":"2023","journal-title":"J Interf Cytokine Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jaci.2022.06.027","article-title":"Novel biologics for treatment of chronic spontaneous Urticaria","volume":"150","author":"Casale","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","article-title":"Burden of illness in adults with atopic dermatitis: analysis of National Health and wellness survey data from France, Germany, Italy, Spain, and the United Kingdom","volume":"81","author":"Eckert","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/1346-8138.14502","article-title":"Impact of chronic Urticaria on quality of life and work in Japan: results of a real-world study","volume":"45","author":"Itakura","year":"2018","journal-title":"J Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ced.14422","article-title":"Psychosocial burden and out-of-pocket costs in patients with atopic dermatitis in Ireland","volume":"46","author":"Murray","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaad.2022.09.054","article-title":"Racial and ethnic differences in barriers to care among us adults with chronic inflammatory skin diseases: a cross-sectional study of the all of us research program","volume":"88","author":"Nock","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed diagnosis of hidradenitis Suppurativa and its effect on patients and healthcare system","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/ddg.15030_g","article-title":"Real-world systemic treatment of patients with psoriasis: a retrospective study based on German claims data","volume":"21","author":"Heidbrede","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s13555-022-00773-3","article-title":"Treatment patterns and healthcare resource utilization among patients with atopic dermatitis: a retrospective cohort study using German health claims data","volume":"12","author":"Schild","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/jdv.14811","article-title":"Guideline-compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria","volume":"32","author":"Schielein","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"adv00560","DOI":"10.2340\/00015555-3901","article-title":"Prescription behaviour and barriers to prescription of biologicals for treatment of chronic inflammatory skin diseases in dermatological practice in two German Federal States","volume":"101","author":"Weiss","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"adv00830","DOI":"10.2340\/actadv.v102.3932","article-title":"Real-world treatment patterns and treatment benefits among adult patients with atopic dermatitis: results from the atopic dermatitis patient satisfaction and unmet need survey","volume":"102","author":"Augustin","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis Suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-021-00539-7","article-title":"Identifying unmet care needs and important treatment attributes in the Management of Hidradenitis Suppurativa: a qualitative interview study","volume":"15","author":"Willems","year":"2022","journal-title":"Patient"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/ddg.14886_g","article-title":"Patient preferences in hidradenitis Suppurativa (approach-Hs): a discrete choice experiment","volume":"20","author":"Faverio","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjd.21798","article-title":"Factors associated with treatment satisfaction in patients with hidradenitis Suppurativa: results from the global voice project","volume":"187","author":"Midgette","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjd.21673","article-title":"The road to biologics in patients with hidradenitis Suppurativa: a Nationwide drug utilization study","volume":"187","author":"Ring","year":"2022","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1384055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:33:22Z","timestamp":1721385202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1384055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":42,"alternative-id":["10.3389\/fmed.2024.1384055"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1384055","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"article-number":"1384055"}}